Abstract
The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection. This is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and clinical outcome assessor. Eligible participants include adults (≥ 18 years) with evidence of SARS-CoV-2 infection by PCR test of nasopharyngeal or oropharyngeal swab within 14 days of randomization, evidence of infiltrates on chest radiography, peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air, and/or need for supplemental oxygen, non-invasive mechanical ventilation, or invasive mechanical ventilation, who are willing and able to provide written informed consent prior to performing study procedures or who have a legally authorized representative available to do so. Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 <24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic...Continue Reading
Citations
Jul 11, 2020·The Cochrane Database of Systematic Reviews·Vanessa PiechottaNicole Skoetz
Jun 18, 2020·Trials·Christina M EckhardtMax R O'Donnell
Jul 28, 2020·International Journal of Molecular Sciences·Alessandra FierabracciPaolo Rossi
Sep 10, 2020·International Journal of Molecular Sciences·Neelu BatraAi-Ming Yu
Oct 13, 2020·The Cochrane Database of Systematic Reviews·Khai Li ChaiNicole Skoetz
Dec 10, 2020·Nature Biomedical Engineering·Shibo JiangLanying Du
Dec 8, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Sondas AlsharidahMedhat Z Askar
Jan 6, 2021·International Journal of Antimicrobial Agents·Charles S Pavia, Gary P Wormser
Nov 7, 2020·The American Journal of Pathology·Eric SalazarJames M Musser
Nov 19, 2020·Trials·Christina M EckhardtMax R O'Donnell
Dec 3, 2020·Risk Management and Healthcare Policy·Nandeeta SamadMainul Haque
Dec 12, 2020·Journal of Extracellular Vesicles·Philip W Askenase
Dec 29, 2020·Frontiers in Immunology·David S KimEster Gea-Mallorquí
Mar 5, 2021·Globalization and Health·Bisi BrightMorenike Oluwatoyin Folayan
Aug 17, 2020·The American Journal of Pathology·Eric SalazarJames M Musser
Apr 8, 2021·JMIR Public Health and Surveillance·Henry T PengAndrew Beckett
Jan 6, 2021·British Journal of Pharmacology·Francesca Levi-Schaffer, Ario de Marco
May 8, 2021·Immunohematology·A D HoS R Stowell
May 21, 2021·The Cochrane Database of Systematic Reviews·Vanessa PiechottaNicole Skoetz
Jun 15, 2021·Vox Sanguinis·Marina IzakEilat Shinar
Jul 3, 2021·Viruses·Massimo FranchiniMarco Zaffanello
May 12, 2021·The Journal of Clinical Investigation·Max R O'DonnellWalter I Lipkin
Jul 13, 2021·Current Clinical Microbiology Reports·Rashed NoorChandrika Saha
Jul 6, 2021·Clinical Trials : Journal of the Society for Clinical Trials·Shing M LeeMagdalena Sobieszczyk
Jul 10, 2021·Thérapie·Shivshankar Malkarjun GunjegaonkarVelayutham Ravichandiran